ArticleFrontiers in aging neuroscience2025
Association between serum tricosanoic acid and cognitive function in older adults: findings from the NHANES and GEO databases.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated transcriptomic and Mendelian randomization analysis identifies novel biomarkers for type 2 diabetes-associated cardiac dysfunction: cynaropicrin as a candidate intervention.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Observational
- Serum lipidomic analysis identifies potential therapeutic targets for neurodegeneration.Frontiers in human neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With global aging, dementia prevalence rises. While long-chain saturated fatty acids show anti-cognitive decline potential, serum tricosanoic acid (C23:0)'s role in brain regions and cognition remains unclear. Methods: To confirm the association between C23:0 and cognition in the population, we analyzed gene expression data from the Alzheimer's disease (AD) brain gene chip data set (GSE118553) available in the Gene Expression Omnibus (GEO) database. Additionally, we examined data from 1,127 adults aged 60 years and older who participated in the National Health and Nutrition Examination Survey (NHANES) between 2011 and 2014. To explore potential metabolic pathways and mechanisms linking C23:0 to cognitive aging, the computational platform METAFlux was employed. Results: Differential gene expression analysis identified 335 downregulated and 477 upregulated genes in AD frontal cortex. Metabolite analysis showed 20 upregulated and 37 downregulated nutrients (including C23:0) in AD vs. controls. Population-level analysis (NHANES, Discussion: This study provides strong evidence for frontal cortex-specific reduced C23:0 in AD and highlights its potential as a serum cognitive marker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.